How biopharmaceutical companies can accelerate indication expansion and repurposing of PIK3CA kinase inhibitors
Repurposing existing cancer drugs can potentially expedite the drug development process, provide
patients with quicker access to life-saving treatments, increase survival rates, and reduce side effects.
In this case study, learn how biopharmaceutical companies can use the Human Somatic Mutation Database
(HSMD) to identify potential new indications for existing cancer therapies.
Download the case study
Thank you for your interest. A sales team member will contact you shortly.
* Mandatory fields
Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. All information you provide in this site will be governed by our Privacy Policy.